Condition
Antiviral Toxicity
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 4 (2)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04904614Phase 4Completed
Letermovir Use in Heart Transplant Recipients
NCT05626530Phase 4Recruiting
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
NCT03251144Phase 1Completed
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Showing all 3 trials